Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Market Cap	29.22B
Revenue (ttm)	54.70M +698.0%
Net Income	-439.90M
EPS	-1.52
Shares Out	325.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	975,610
Average Volume	682,879
Open	89.65
Previous Close	89.65
Day's Range	87.25 - 90.95
52-Week Range	56.00 - 206.00
Beta	n/a
RSI	41.41
Earnings Date	Mar 26, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 354
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2659

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY